Brilinta data buoys AstraZeneca stock
This article was originally published in Scrip
Executive Summary
AstraZeneca's shares received a boost on 14 January after the company revealed positive data from its latest study of heart drug Brilinta (ticagrelor). Investors seemed hopeful that these data may eventually get the company closer to its ambitious sales targets for Brilinta.